Cardiotoxic Effects of Osimertinib Compared to Other EGFR Inhibitors: A Systematic Review and Meta-Analysis - PubMed
3 days ago
- #Cardiotoxicity
- #Osimertinib
- #EGFR inhibitors
- Osimertinib, a third-generation EGFR inhibitor, is used for EGFR-mutant NSCLC but has been linked to cardiotoxic effects.
- A systematic review and meta-analysis compared Osimertinib's cardiotoxicity to other EGFR inhibitors, involving 19,008 patients.
- Osimertinib was associated with increased risks of heart failure (RR = 1.45), decline in LVEF (RR = 3.10), and myocardial infarction (RR = 1.40).
- No significant differences were found in the risk of arrhythmias and pericardial effusion compared to other EGFR inhibitors.
- The study recommends proactive cardiac monitoring for patients on Osimertinib, especially those with pre-existing risk factors.